Transition period financial data (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended																				6 Months Ended					12 Months Ended
	Dec. 31, 2015		Sep. 26, 2015		Jun. 27, 2015		Mar. 28, 2015		Dec. 27, 2014		Sep. 27, 2014		Jun. 28, 2014		Mar. 29, 2014		Dec. 28, 2013		Sep. 28, 2013		Dec. 31, 2015		Dec. 27, 2014	Dec. 28, 2013	[1]	Jun. 27, 2015		Jun. 28, 2014	Jun. 29, 2013
Net sales	$ 1,424.8		$ 1,344.7		$ 1,531.6		$ 1,049.1		$ 1,071.7		$ 951.5		$ 1,144.2		$ 1,004.2		$ 979.0		$ 933.4		$ 2,769.5		$ 2,023.1			$ 4,603.9		$ 4,060.8	$ 3,539.8
Cost of sales																					1,661.4		1,317.6			2,891.4		2,613.1	2,259.8
Gross profit	559.3		548.8		628.1		378.8		383.8		321.8		415.7		315.0		360.7		356.3		1,108.1		705.5			1,712.5		1,447.7	1,280.0
Distribution																					47.9		29.2			67.7		55.3	47.5
Research and development																					88.2		89.8			187.8		152.5	115.2
Selling																					325.9		95.3			319.0		208.6	186.1
Administration																					309.1		165.5			385.2		411.3	240.2
Impairment charges																					215.6		0.0			0.0		0.0	0.0
Restructuring	24.7												10.5		19.5		14.9				26.9		4.2			5.1		47.0	2.9
Total operating expenses																					1,013.6		384.0			964.8		880.7	600.9
Operating income																					94.5	[1]	321.5	$ 567.0		747.7	[1]	567.0	679.1	[1]
Interest expense, Net																					(89.9)		(56.7)			(146.0)		(103.5)	(65.8)
Other expenses, net																					26.9		61.9			343.2		25.1	5.6
Loss on extinguishment of debt									(9.6)								(165.8)				0.9		9.6			10.5		165.8	0.0
Income (loss) before income taxes																					(23.2)		193.3			248.0		272.6	607.7
Income tax expense (benefit)																					(28.8)		26.8			120.0		67.3	165.8
Net income (loss)	$ (107.0)	[2]	$ 112.6	[3]	$ 56.4	[4]	$ (94.9)	[5]	$ 70.2	[6]	$ 96.3		$ 131.7	[7]	$ 48.1	[8]	$ (86.0)	[9]	$ 111.4	[10]	$ 5.6		$ 166.5			$ 128.0		$ 205.3	$ 441.9
Earnings (loss) per share, basic	$ (0.74)	[2],[11]	$ 0.77	[3],[11]	$ 0.39	[4],[11]	$ (0.67)	[5],[11]	$ 0.52	[6],[11]	$ 0.72	[11]	$ 0.98	[7],[11]	$ 0.36	[8],[11]	$ (0.87)	[9],[11]	$ 1.18	[10],[11]	$ 0.04		$ 1.23			$ 0.92		$ 1.78	$ 4.71
Earnings (loss) per share, diluted	$ (0.74)	[2],[11]	$ 0.77	[3],[11]	$ 0.38	[4],[11]	$ (0.67)	[5],[11]	$ 0.51	[6],[11]	$ 0.72	[11]	$ 0.98	[7],[11]	$ 0.36	[8],[11]	$ (0.87)	[9],[11]	$ 1.18	[10],[11]	$ 0.04		$ 1.23			$ 0.92		$ 1.77	$ 4.68
Basic	144.9		146.3		146.3		140.8		136.3		133.9		133.8		133.7		98.7		94.2		145.6		135.1			139.3		115.1	93.9
Weighted Average Number of Shares Outstanding, Diluted	144.9		146.9		146.8		140.8		136.8		134.4		134.3		134.3		98.7		94.7		146.1		135.6			139.8		115.6	94.5
Dividends declared per share																					$ 0.25		$ 0.21			$ 0.46		$ 0.39	$ 0.35

[1] Amounts may not cross-foot due to rounding.

[2] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million.

[3] Includes Mylan defense-related fees of $15.6 million.

[4] Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees.Twelve Months Ended June 28, 2014FirstQuarter(2) SecondQuarter(3) ThirdQuarter(4) FourthQuarter(5)Net sales$933.4 $979.0 $1,004.2 $1,144.2Gross profit$356.3 $360.7 $315.0 $415.7Net income (loss)$111.4 $(86.0) $48.1 $131.7Earnings (loss) per share(1): Basic$1.18 $(0.87) $0.36 $0.98Diluted$1.18 $(0.87) $0.36 $0.98Weighted average shares outstanding Basic94.2 98.7 133.7 133.8Diluted94.7 98.7 134.3 134.3

[5] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million.

[6] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million

[7] Includes a loss contingency of $15.0 million related to Texas Medicaid and restructuring charges totaling $10.5 million

[8] Includes restructuring charges totaling $19.5 million

[9] Includes loss on extinguishment of debt of $165.8 million, Elan transaction costs of $103.2 million, and restructuring charges totaling $14.9 million

[10] Includes Elan transactions costs of $12.0 million

[11] The sum of individual per share amounts may not equal due to rounding.